NCT00181558View on ClinicalTrials.gov

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Prostate CancerAdenocarcinoma of the Prostate
Interventions
DRUG

Atrasentan

DRUG

Zoledronic Acid (Zometa)

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Abbott

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00181558 - Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | Biotech Hunter | Biotech Hunter